ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2020
Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 102 citations in OpenAlex.
- Enzyme/Reactive Oxygen Species-Dually Activated Hyaluronic Acid Nanocarriers Enable Celastrol Delivery for Site-Specific Therapy of Inflammatory Bowel Diseases and Colorectal Cancer.International journal of nanomedicine · 2026Article
- Tumor microenvironment-activated ROS enhancers for effective inhibition of osteosarcoma.BMC biotechnology · 2025Article
- MXene-Integrated Composites for Biomedical Applications: Synthesis, Cancer Diagnosis, and Emerging Frontiers.Small science · 2025Review
- A pyroptosis proportion tunable nano-modulator for cancer immunotherapy.Theranostics · 2025Article
- Targeted and intelligent nano-drug delivery systems for colorectal cancer treatment.Frontiers in bioengineering and biotechnology · 2025Review
- The role of Treg cells in colorectal cancer and the immunotherapy targeting Treg cells.Frontiers in immunology · 2025Review
- Photodynamic Therapy as a Desirable Approach in the Treatment of Colorectal Cancer, with Special Focus on Photodynamic Nanotherapeutics in Immunotherapy.Current medicinal chemistry · 2025Review
- Improving the Anti-Tumor Effect of Indoleamine 2,3-Dioxygenase Inhibitor CY1-4 by CY1-4 Nano-Skeleton Drug Delivery System.Journal of functional biomaterials · 2024Article
- Supramolecular Nano-Tracker for Real-Time Tracking of Drug Release and Efficient Combination Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Recent Advances of Natural Pentacyclic Triterpenoids as Bioactive Delivery System for Synergetic Biological Applications.Foods (Basel, Switzerland) · 2024Review
- From structural design to delivery: mRNA therapeutics for cancer immunotherapy.Exploration (Beijing, China) · 2024Review
- Therapeutic Supramolecular Polymers: Designs and Applications.Progress in polymer science · 2024Article
- Hyperosmotic cold shock mouse melanoma cells encapsulated with doxorubicin for targeted treatment of melanoma.Frontiers in oncology · 2024Article
- Cancer Cell-Specific Fluorescent Prodrug Delivery Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Bionic natural small molecule co-assemblies towards targeted and synergistic Chemo/PDT/CDT.Biomaterials research · 2023Article
- Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.International journal of molecular sciences · 2023Review
- Recent Development of Supramolecular Cancer Theranostics Based on Cyclodextrins: A Review.Molecules (Basel, Switzerland) · 2023Review
- Natural Polymeric Composites Derived from Animals, Plants, and Microbes for Vaccine Delivery and Adjuvant Applications: A Review.Gels (Basel, Switzerland) · 2023Review
- The State of the Art of Natural Polymer Functionalized FeGels (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy aiming to harness the exquisite power of the immune system has emerged as a crucial part of clinical cancer management. However, only a subset of cancer patients responds to current immunotherapy because of low immunogenicity of the tumor cells and immunosuppressive tumor microenvironment. Herein, host-guest prodrug nanovectors are reported for active tumor targeting and combating immune tolerance in tumors. The prodrug nanovectors are designed by integrating hyaluronic acid (HA) and reduction-labile heterodimer of Pheophorbide A (PPa) and NLG919 into the supramolecular nanocomplexes, where PPa and NLG919 act as a photosensitizer and potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO-1), respectively. Meanwhile, HA is employed to achieve active tumor targeting by recognizing CD44 overexpressed on the surface of tumor cell membranes. Near infrared (NIR) laser irradiation triggers the release of reactive oxygen species to provoke antitumor immunogenicity and intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Meanwhile, the immunosuppressive tumor microenvironment (ITM) is reversed by NLG919-mediated IDO-1 inhibition. Combination of photodynamic immunotherapy and IDO-1 blockade efficiently eradicates CT26 colorectal tumors in the immunocompetent mice. The host-guest nanoplatform capable of eliciting effective antitumor immunity by inactivating inhibitory immune response can be applied to other immune modulators for improved cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.